Silo Pharma Inc.

SILO


Canadian symbol: SILO
US symbol: SILO

Currency in USD

Valuation Measures

Market Cap (intraday) 525.55M
Enterprise Value 321.46M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)624.42
Price/Book (mrq)N/A
Enterprise Value/Revenue 3524.45
Enterprise Value/EBITDA 7N/A

Trading Information

Stock Price History

Beta (5Y Monthly) -1.81
52-Week Change 3-24.29%
S&P500 52-Week Change 343.61%
52 Week High 30.4950
52 Week Low 30.2200
50-Day Moving Average 30.2772
200-Day Moving Average 30.3132

Share Statistics

Avg Vol (3 month) 3220.65k
Avg Vol (10 day) 3156.76k
Shares Outstanding 585.18M
Implied Shares Outstanding 6N/A
Float 73.88M
% Held by Insiders 115.36%
% Held by Institutions 10.00%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2020
Most Recent Quarter (mrq)Dec. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-6,287.34%

Management Effectiveness

Return on Assets (ttm)-167.47%
Return on Equity (ttm)-366.45%

Income Statement

Revenue (ttm)40.92k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)-45.10%
Gross Profit (ttm)-135.2k
EBITDA N/A
Net Income Avi to Common (ttm)-3.11M
Diluted EPS (ttm)N/A
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.13M
Total Cash Per Share (mrq)0.01
Total Debt (mrq)18.9k
Total Debt/Equity (mrq)1.48
Current Ratio (mrq)10.07
Book Value Per Share (mrq)N/A

Cash Flow Statement

Operating Cash Flow (ttm)-1.16M
Levered Free Cash Flow (ttm)-172.04k

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.




Company News Date
SILO
Silo Pharma
4 months ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
15.36%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Silo Pharma Inc.


Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Agreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has finalized an agreement to sublicense the technology covered by its recently annou... Read More...

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Englewood Cliffs, NJ, Jan. 26, 2021 -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised i... Read More...

Silo Pharma Inc. Discusses The Potential of Merging Traditional Therapeutics with Psychedelic Research On The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - January 20, 2021) - The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB: SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other ... Read More...

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous SystemEnglewood Cliffs, NJ, Jan. 13, 2021 -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PT... Read More...

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

Englewood Cliffs, NJ, Jan. 11, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million.  The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a li... Read More...

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Englewood Cliffs, NJ, Jan. 06, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent ... Read More...

Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin

Englewood Cliffs, NJ, Dec. 15, 2020 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named clinical researcher and professor, Dr. Charles B. Nemeroff, M.D., Ph.D., to its Scientific Advisory Board.Dr. Nemero... Read More...

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

NEW JERSEY, Dec. 07, 2020 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named behavioral health expert Dr. Peter Hendricks, Ph.D. to its newly formed Scientific Advisory Board.Dr. Peter Hendricks is an As... Read More...

Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets

NEW JERSEY , Dec. 04, 2020 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has been requested by the OTC Markets Group (“the OTC Markets”) to comment on recent promotional activity.The Company became aware of certain promotional a... Read More...

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease

Collaboration with the University of Maastricht of the NetherlandsSilo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an investigator-sponsored study agreement with Maastricht University of the Netherlands. The research... Read More...

Silo Pharma, Inc. Expands Scientific Advisory Board with the Appointment of Dr. Joshua Woolley of University of California, San Francisco

NEW YORK , Nov. 16, 2020 -- Silo Pharma, Inc. (OTCQB: SILO) today announced that its Board of Directors has named scientific research investigator Dr. Joshua Woolley, M.D. / Ph.D. to its newly formed Scientific Advisory Board.Dr. Joshua Woolley M.D. / Ph.D. is an Associate Professor in Residence, Department of Psychiatry at the University... Read More...

Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Dr. Matthew Johnson of John Hopkins University

Industry Recognized Expert in Psychedelics and Related Safety GuidelinesNEW YORK, Nov. 09, 2020 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced it has formed a Scientific Advisory Board for evaluating opportunities to advance strategies r... Read More...
Coming Soon.

Delayed data (1h)


Share this page